摘要
目的采用代谢组学技术检测分析肝硬化合并肝性脑病患者血清代谢产物水平。方法选取18例肝硬化合并肝性脑病患者和53例肝硬化未合并肝性脑病患者,采用超高效液相色谱-串联质谱(UPLC-MS/MS)和常规生化分析检测血清样品,比较分析血清代谢产物水平和常规生化指标水平。结果与肝硬化对照组比较,肝性脑病组患者血氨水平及血清中乙酰半胱氨酸、乙酰氨基、4-乙酰氨基丁酸、L-苯乙酰谷氨酰胺、苯丙氨酸、酪氨酸、奎宁酸、阿拉伯醇、乙酰肉碱和犬尿氨酸水平升高,差异有统计学意义(P<0.05);2组间WBC、Hb、PLT、INR、ALT、Sr、Alb水平比较,差异无统计学意义(P>0.05)。结论采用代谢组学方法筛选的肝硬化合并肝性脑病患者的差异性代谢产物,可为临床肝性脑病的诊断和治疗提供一定的实验基础。
Objective To analyze the serum metabolites in patients with liver cirrhosis complicated with hepatic encephalopathy by metabonomics.Methods Eighteen patients with liver cirrhosis complicated with hepatic encephalopathy and 53 patients with liver cirrhosis without hepatic encephalopathy were involved.Serum samples were detected by ultra-high performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS)and routine biochemical analysis.The serum levels of metabolites and routine biochemical indexes were compared and analyzed.Results The ammonia level and the serum levels of acetylcysteine,acetylamino,4-acetylaminobutyric acid,L-phenylacetylglutamine,phenylalanine,tyrosine,quinic acid,arabinol,acetylcarnitine and kynurenine in the liver cirrhosis complicated with hepatic encephalopathy group were higher than those in the hepatic encephalopathy without hepatic encephalopathy(P<0.05).No significant difference in the levels of WBC,Hb,PLT,INR,ALT,Sr and Alb were observed between the two groups(P>0.05).Conclusions The differential metabolites of liver cirrhosis complicated with hepatic encephalopathy screened by metabonomics method can provide certain experimental basis for the diagnosis and treatment of clinical hepatic encephalopathy.
作者
李立峰
胡公义
侯若南
吴和
齐艳红
LI Lifeng;HU Gongyi;HOU Ruonan;WU He;QI Yanhong(Department of Emergency Medicine,the Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China;General Medicine Department,the Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China)
出处
《健康研究》
CAS
2021年第4期412-415,共4页
Health Research
基金
温州市公益性科技计划项目(Y20170739,Y20180503)。
关键词
代谢组学
肝性脑病
肝硬化
代谢标志物
metabonomics
hepatic encephalopathy
liver cirrhosis
metabolic markers
